Comments
Aurobindo Pharma Limited has announced that the company has received the final approval from the US Food & Drug Administration to manufacture and market Entecavir Tablets, 0.5mg and 1mg.
The approved Abbreviated New Drug Application is bioequivalent and therapeutically equivalent to the reference listed drug product (RLD) Baraclude tablets, 0.5mg and 1mg, of Bristol-Myers Squibb.
Entecavir tablets are indicated for treatment of chronic hepatitis B virus infection of the liver. The product has an estimated market size of $ 294 million for the twelve months ending June 2015 according to IMS.
This is the 44th ANDA to be approved out of Unit VII formulation facility in Hyderabad for manufacturing oral non-antibiotic products. Aurobindo now has a total of 209 ANDA approvals (181 Final approvals including 9 from Aurolife Pharma LLC and 28 tentative approvals) from USFDA.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.